MorphoSys AG: The Evolution of a Biotechnology Business Model Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for MorphoSys AG: The Evolution of a Biotechnology Business Model case study

At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. MorphoSys AG: The Evolution of a Biotechnology Business Model case study is a Harvard Business School (HBR) case study written by Gary P. Pisano, Ryan Johnson, Carin-Isabel Knoop. The MorphoSys AG: The Evolution of a Biotechnology Business Model (referred as “Morphosys Proprietary” from here on) case study provides evaluation & decision scenario in field of Technology & Operations. It also touches upon business topics such as - Value proposition, Joint ventures, Research & development, Risk management, Strategic planning, Strategy execution.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment

---

Case Description of MorphoSys AG: The Evolution of a Biotechnology Business Model Case Study

In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently, the company decided to deviate from this model, and attempt to develop its own proprietary products. The case allows analysis of "license vs. vertically integrate" business model decisions, and can be used to teach principles of business model design and the functioning of markets for know-how.

Case Authors : Gary P. Pisano, Ryan Johnson, Carin-Isabel Knoop

Topic : Technology & Operations

Related Areas : Joint ventures, Research & development, Risk management, Strategic planning, Strategy execution

---

Calculating Net Present Value (NPV) at 6% for MorphoSys AG: The Evolution of a Biotechnology Business Model Case Study

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 6 %	Discounted Cash Flows
Year 0	(10027917)	-10027917	-	-
Year 1	3469962	-6557955	3469962	0.9434	3273549
Year 2	3960143	-2597812	7430105	0.89	3524513
Year 3	3948066	1350254	11378171	0.8396	3314872
Year 4	3242870	4593124	14621041	0.7921	2568657
TOTAL			14621041		12681591

The Net Present Value at 6% discount rate is 2653674

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting

What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.

---

Capital Budgeting Approaches

Methods of Capital Budgeting

There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Net Present Value
3. Profitability Index
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Morphosys Proprietary shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Morphosys Proprietary have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.

---

Formula and Steps to Calculate Net Present Value (NPV) of MorphoSys AG: The Evolution of a Biotechnology Business Model

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Technology & Operations Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Morphosys Proprietary often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Morphosys Proprietary needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 15 %	Discounted Cash Flows
Year 0	(10027917)	-10027917	-	-
Year 1	3469962	-6557955	3469962	0.8696	3017358
Year 2	3960143	-2597812	7430105	0.7561	2994437
Year 3	3948066	1350254	11378171	0.6575	2595917
Year 4	3242870	4593124	14621041	0.5718	1854121
TOTAL					10461834

The Net NPV after 4 years is 433917

(10461834 - 10027917 )

---

Calculating Net Present Value (NPV) at 20%

If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 20 %	Discounted Cash Flows
Year 0	(10027917)	-10027917	-	-
Year 1	3469962	-6557955	3469962	0.8333	2891635
Year 2	3960143	-2597812	7430105	0.6944	2750099
Year 3	3948066	1350254	11378171	0.5787	2284760
Year 4	3242870	4593124	14621041	0.4823	1563884
TOTAL					9490379

The Net NPV after 4 years is -537538

At 20% discount rate the NPV is negative (9490379 - 10027917 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Morphosys Proprietary to discount cash flow at lower discount rates such as 15%.

Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Morphosys Proprietary has a NPV value higher than Zero then finance managers at Morphosys Proprietary can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Morphosys Proprietary, then the stock price of the Morphosys Proprietary should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Morphosys Proprietary should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What will be a multi year spillover effect of various taxation regulations.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What can impact the cash flow of the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.

---

Negotiation Strategy of MorphoSys AG: The Evolution of a Biotechnology Business Model

References & Further Readings

Gary P. Pisano, Ryan Johnson, Carin-Isabel Knoop (2018), "MorphoSys AG: The Evolution of a Biotechnology Business Model Harvard Business Review Case Study. Published by HBR Publications.